Home › Clinical Trials › Cancer Clinical Trial › Pancreas › MM-398-07-02-03: A randomized, open-label phase 2 study of irinotecan liposomal injection (lip-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated, metastatic pancreatic adenocarcinoma
Important information about COVID-19 ›

MM-398-07-02-03: A randomized, open-label phase 2 study of irinotecan liposomal injection (lip-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated, metastatic pancreatic adenocarcinoma

UCI-17-103
NCT02551991
Cancer - Pancreas
Farshid Dayyani
Open
Treatment
II
Adult
National

For information about cancer clinical trials at the UCI Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.